( ) saw a notable decline in short interest during the month of may. On May 31, there were 19,120,000 shorted shares. This is a decrease of 10.2% compared to the total of 21,300,000.000 shares on May 15. The short-interest rate is 7.6 days based on an average daily volume of 2,520,000 share.
Amicus Therapeutics Trading up 1.0 %
On Friday, the stock rose $0.13 to $13.09. The stock was traded at a volume of 4,157,752 compared to the average of 2,738,694. Amicus Therapeutics' 52-week low is $8.48, and its 52-week highest is $13.84. The debt-to equity ratio for the company is 3.83. Its current ratio is 2.89, and its quick ratio is 2.69. The company's market capitalization is $3.73 billion. It has a P/E ratio of -18.70, and a beta value of 0.80. The last time ) released its quarterly earnings was on May 10th. The biopharmaceutical firm reported ($0.18) in earnings per share during the first quarter. This was below the consensus estimate ($0.13) of ($0.13). Amicus Therapeutics reported a negative return of equity of 153.68%, and a net margin of 60.63 %. The company had revenue of $86.27 million in the third quarter compared with analysts' expectations of $82 1.14 million. Amicus Therapeutics is expected to post a -0.48 earnings per share for the current fiscal year, according to research analysts.
Analyst Upgrades and downgrades
Recent comments from several equity research analysts on FOLD's shares. Amicus Therapeutics was covered in a report published on Thursday, 18th May. The stock was given a "buy" rating. UBS Group raised their price target for Amicus Therapeutics to $17.00 in a report published on Thursday, 2nd March. They also gave the company a "buy" rating. Goldman Sachs Group raised its price target for Amicus Therapeutics to $11.00 from $10 and gave it a neutral rating in an article published on Thursday, 2nd March. Four analysts have given the stock a buy recommendation, while two have given it a hold. MarketBeat data shows that Amicus Therapeutics currently has a consensus of 'Moderate buy' with an average price of $15.20.
Amicus Therapeutics: Insider Deals
On Monday, April 3, 2011, the company sold 11,700 shares. Stock was sold for $11.21 on average, resulting in a $131,157.00 transaction. After the completion of this transaction, the CEO now owns directly 823,454 company shares, valued at $9.230,919.34. On Monday, April 3, 2011, the company sold 11,700 shares. Stock was sold for $11.21 on average, resulting in a $131,157.00 transaction. After the transaction was completed, the chief executive now owns directly 823,454 company shares, valued at $9.230,919.34. The business sold 8,300 shares in a transaction on Tuesday, 6th June. Stock was sold for $103,750.00 at an average price $12.50. After the transaction, the CEO now owns 8,15,154 shares worth $10,189.425. Insiders have sold 73.620 shares worth $851.717 in the past three months. Insiders hold 2.10% the stock of their company.
Hedge Funds weigh in on Amicus Therapeutics
A number of institutional investors and hedge fund managers have recently increased or decreased their stakes in FOLD. US Bancorp DE increased its stake in Amicus Therapeutics during the first quarter by 16,809.0%. US Bancorp DE owns 15,049 of the biopharmaceutical stock valued at $143,000, after buying an additional 14,960 in the last quarter. MetLife Investment Management LLC increased its holdings of Amicus Therapeutics shares by 53.3% in the first quarter. MetLife Investment Management LLC owns 145 476 shares of Amicus Therapeutics' stock, valued at $1 378 000, after purchasing an additional 50 600 shares during the last quarter. Mariner LLC increased its holdings of Amicus Therapeutics shares by 15.5% in the first quarter. Mariner LLC owns 26,338 of the biopharmaceutical stock, valued at $249,000, after purchasing an additional 3,539 in the last quarter. Charles Schwab Investment Management Inc. increased its holdings of shares of Amicus Therapeutics during the first quarter by 2.4%. Charles Schwab Investment Management Inc. owns 2,004,734 of the biopharmaceutical stock, valued at $18,985,000. This is after adding 47,117 additional shares during the last quarter. UBS Group AG increased its holdings of Amicus Therapeutics shares by 7.7% in the first quarter. UBS Group AG owns 512.442 shares worth $4,853,000 of the biopharmaceutical firm's stock after adding 36.572 more shares during the last quarter.
Amicus Therapeutics, Inc., a biotechnology firm, is focused on finding, developing, and delivering drugs for rare diseases. Galafold is a precision medicine that can be taken orally by adults who have Fabry's disease confirmed and a gene variant with an amenable expression based on data from in vitro tests.
MarketBeat.com offers a FREE daily email newsletter